Advertising
Showing 1 to 15 of 43 entries
BUY
Healthcare thrives when economies slow.
E.T.F.'s
BUY
Allan Tong’s Discover Picks XLV ETF’s top holdings are Johnson & Johnson, UnitedHealth Group, Pfizer, Abbott Labs, AbbVie, Thermo Fisher, Merck, Eli Lilly and Danaher. A bullish case can be made for almost all all these names. Another plus: the MER is only 0.1%, though the dividend pays a lowly 1.4%. XLV’s PE is merely 6.62%, volumes average a healthy 14.8 billion a day, and its beta is a very stable 0.73. While you can make better gains holding some of the stocks this ETF holds, XLV is a safe way to play the American healthcare stocks in 2022. Read 3 Promising Healthcare Stocks for our full analysis.
E.T.F.'s
BUY
He likes healthcare, given the return to preventative care and elective surgeries. Also, there's a strong pharma pipeline. Stay long in health.
E.T.F.'s
BUY
Allan Tong’s Discover Picks However, if you want to own several in one place or can’t afford to buy one of these stocks individually, XLV is the place to go. It trades on the Nasdaq. It charges an ultra-low MER of 0.12%, trades at merely 4.18x PE and pays a 1.4% dividend. Also, average volumes are a robust 13.9 million and the Beta is a low 0.71. YTD, XLV has lost 7.55%, but Omicron was the major disruptor and restrictions are quickly lifting now. Essentially, you’re buying this ETF for the future. Read 3 Best Cyclical and Value ETFs for our full analysis.
E.T.F.'s
BUY
Healthcare stock with a 5-year horizon? She prefers owning individual names, but XLV includes Thermo-Fisher, BMO, Abbott, etc. Healthcare will change a lot in coming years, and XLV gives you a good representation.
E.T.F.'s
BUY
XLV vs. IBB Has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.
E.T.F.'s
PAST TOP PICK
(A Top Pick May 05/21, Up 14%) Recently pulled up again, with defensive sectors doing quite well. He sold in October. Longer term, in 2022, healthcare will be a good sector to be in. Put it on the back burner for now, and take a look again in May.
E.T.F.'s
BUY
Long-term, really likes the sector. When things are hot, the sector may lag. XLV has about 65 names. Aging demographics, growing emerging markets and middle class, increased healthcare spending. This year, healthcare ranks #8 out of 11 sectors. But if you're concerned about the long term, which he thinks you should be, XLV is a good place to start.
E.T.F.'s
DON'T BUY

Better to buy the holdings? He doesn't buy ETFs, because he's an active manager. He'd rather buy the individual stocks, and he doesn't know what's in this ETF, though Thermo-Fisher, a key holding, is a fine company. In this sector, he owns Anthem, Abbvie and CVS, for example. Healthcare isn't in the sun now, but you can do well if you pick the right stocks.

E.T.F.'s
TOP PICK
There's been talk of change of the US healthcare system for years, but Covid is making it difficult to do that right now and makes healthcare protected from attack. Strong seasonal period right now. Elective surgeries coming back. Huge opportunity for an uptick at least until August. Yield is 1.39%.
E.T.F.'s
PAST TOP PICK
(A Top Pick May 07/20, Up 8%) Healthcare sector is a bit exhausted right now, and seeing relative weakness. He's walked back from it a bit. Coming up to an election, healthcare can become a political football.
E.T.F.'s
TOP PICK
The healthcare sector has outperformed the S&P since February. There is a lot of money going into this sector. It tends to do well this time of year also. We also have to be more cautious in election years but it will be harder for this sector to be kicked back and forth like a football.
E.T.F.'s
PAST TOP PICK
(A Top Pick May 09/19, Up 4%) Seasonality ends Oct. 24. It's been faltering lately. The US election campaign is a headwind and will continue to overhang. He may exit this.
E.T.F.'s
PAST TOP PICK
(A Top Pick Sep 12/18, Down 1%) He was stopped out of this. The medical devices space is good. Biotech services, are under huge pressure. This ETF was a little too inclusive so he exited.
E.T.F.'s
COMMENT

US Healthcare For knee replacements and implants he likes SNN-N. He does not prefer the ETFs, such as XLV-N, because they hold too broad of an array of companies, including the big drug companies that are under pressure. He would focus on the tool and device space instead.

E.T.F.'s
Showing 1 to 15 of 43 entries

Market Summary > Health Care Select Sector SPDR Fund(XLV-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 8

Stockchase rating for Market Summary > Health Care Select Sector SPDR Fund is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Market Summary > Health Care Select Sector SPDR Fund(XLV-N) Frequently Asked Questions

What is Market Summary > Health Care Select Sector SPDR Fund stock symbol?

Market Summary > Health Care Select Sector SPDR Fund is a American stock, trading under the symbol XLV-N on the NYSE Arca (XLV). It is usually referred to as AMEX:XLV or XLV-N

Is Market Summary > Health Care Select Sector SPDR Fund a buy or a sell?

In the last year, 8 stock analysts published opinions about XLV-N. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Market Summary > Health Care Select Sector SPDR Fund.

Is Market Summary > Health Care Select Sector SPDR Fund a good investment or a top pick?

Market Summary > Health Care Select Sector SPDR Fund was recommended as a Top Pick by on . Read the latest stock experts ratings for Market Summary > Health Care Select Sector SPDR Fund.

Why is Market Summary > Health Care Select Sector SPDR Fund stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Market Summary > Health Care Select Sector SPDR Fund worth watching?

8 stock analysts on Stockchase covered Market Summary > Health Care Select Sector SPDR Fund In the last year. It is a trending stock that is worth watching.

What is Market Summary > Health Care Select Sector SPDR Fund stock price?

On 2022-06-24, Market Summary > Health Care Select Sector SPDR Fund (XLV-N) stock closed at a price of $129.2.